NanoXplore and Molding Products Execute Long Term Supply Agreement for GrapheneBlack Enhanced Composite Materials for Transportation Market

NanoXplore Inc. (" NanoXplore " or the " Corporation ") (TSX: GRA and OTCQX: NNXPF) announces that it has entered into a long-term supply agreement with Molding Products LLC to produce and sell graphene-enhanced Sheet Molding Compound ("SMC") called GrapheneBlack™ SMC, used to create high quality, lightweight composite exterior and battery enclosure parts for cars and trucks, such as hoods, bumpers, roofs, and battery packs. GrapheneBlack™ SMC delivers weight reduction of up to 15% vs typical composite parts while also improving surface finish, paintability, and crack resistance. Under the terms of the agreement, both companies can market and sell the new premium grade of SMC under the NanoXplore tradename. Weight reduction is becoming increasingly important for the transportation industry, particularly because electric vehicles are generally heavier than internal combustion engine vehicles and range anxiety could be addressed by reducing the weight of the vehicles. Furthermore, lightweight sheet molding composites are being used increasingly in electric vehicle battery packs that would be complementary to NanoXplore battery related activities.

The agreement with NanoXplore secures a competitive, localized supply of high-quality graphene to produce GrapheneBlack™ SMC as well as R&D support for the development of new graphene-enhanced product grades. NanoXplore is the world's largest manufacturer of sustainable, high-quality, cost-effective graphene with 4,000 metric tons of annual production capacity in Montreal, Canada.

Troy Wade, President of Molding Products, commented:

"This is a great opportunity to advance Molding Products' SMC technology as we look to expand further into the transportation market space. By combining NanoXplore graphene with our own proprietary SMC technology, we can deliver significant weight savings with superior properties for the end-user's application."

Soroush Nazarpour, President and Chief Executive Officer of NanoXplore, commented:

"I am very pleased that our graphene and graphene-enhanced composite products passed the stringent qualification process for the transportation market. The alliance with Molding Products introduces graphene-enhanced composite products into exterior and battery enclosures parts of the passenger vehicle market as well as heavy commercial vehicles and buses. The resulted weight reduction translates into longer range for electric vehicles and can be used in other transportation segments such as trains and planes."

About NanoXplore Inc.

NanoXplore is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in transportation and industrial markets. The Company provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. NanoXplore is headquartered in Montreal, Quebec with manufacturing facilities across North America and Europe. Please visit www.nanoxplore.ca .

About Molding Products

Headquartered in South Bend Indiana, Molding Products LLC, an operating business of IP Corporation, supplies sheet molding composites to the growing compression molding industry with a focus on providing industry-leading, custom-formulated molding compounds for a wide variety of industries and applications.

For further information, please contact:

Martin Gagné
Director, Investor Relations
Martin.gagne@nanoxplore.ca
Tel: 438.476.1342

Todd Cummings
Technical Sales Lead
tcummings@molding-products.com
Tel: 704.402.7114


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

GRA:CA,NNXPF
The Conversation (0)
Sona Nanotech

Sona Nanotech Grants Options

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has granted 25,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to a consultant. Each option is exercisable into one common share at a price of $0.30 per share... Keep Reading...
Sona Nanotech

Sona Nanotech

Get access to more exclusive Nanotech Investing Stock profiles here Keep Reading...
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024. Details for the Company's presentation: Date: Wednesday, June 12, 2024 Time:... Keep Reading...
Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two... Keep Reading...
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI's Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cuts the 5-year risk... Keep Reading...

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide... Keep Reading...

Latest Press Releases

Related News